Immunalgia Therapeutics

Immunalgia Therapeutics is a biotechnology company dedicated to the development of novel treatments for chronic pain by targeting the neuro-immune system. The company's approach focuses on "reprogramming" the immune response to promote the resolution of inflammation and the regeneration of damaged nerves, rather than merely masking pain signals. Its lead program, IMT-002, utilizes a repurposed biologic to treat neuropathic pain conditions such as Complex Regional Pain Syndrome. Headquartered in Argentina, the company aims to address the significant unmet need for non-opioid pain therapies through its unique neuro-immunological insights. Immunalgia was incubated by GRIDX and maintains strong ties to academic research institutions in South America.